

Progress Report: Sri Lanka Clinical Trials Registry

SLCTR registration number: SLCTR/2022/028

Scientific title of trial: Phase 2/3, Multicenter, Open-label Trial to Evaluate the Long-term Safety, Tolerability, and Efficacy of Sibeprenlimab Administered Subcutaneously in Subjects with Immunoglobulin A Nephropathy

Date of commencement (enrolment of first participant): 24 Jan 2023

Progression: 6 months 1 year 2 years 3 years
At completion

1. Baseline data

Any changes to the trial design/ methodology/ protocol after commencement: Yes

Any changes to trial outcomes after commencement: Yes

2. Current status

Recruitment status: follow up continuing

Number assessed for eligibility: 05

Number recruited and allocated/randomized: 05

Number allocated/randomized to each intervention/arm (please edit as relevant): Not applicable as this is an open label study

Arm 1:

Arm 2:

Losses/exclusions after allocation/randomization (please edit as relevant): Not applicable as this an open label study

Arm 1:

Arm 2:

3. Trial output

Date of trial completion ("last patient, last visit"): Not applicable

Final sample size:

Summary of Interim/Final data (if available):

Not available

Abstract presentations of results at scientific meetings


Note: please include a URL link or scanned copy of the abstract

Title of Abstract	Full citation (please include authors, date, title of conference and place of presentation, page number of abstract).

Publications

Note: please include a URL link or scanned copy of the publication

Title of paper	Full citation (please include authors, title of journal, volume, issue and page numbers, and/or DOI)


.....
Name and signature of Responsible Registrant/
Principal Investigator: Prof. Eranga Wijewickrama

Date: 26 Nov 2024